News
DMCR joined hands with Future Care Clinical Research in Springfield, MA to form DM Future Care Clinical Research, LLC. The business name will be changed to DM Clinical Research and will be a Hub site for the DMCR operation. This is a dedicated research site that has been serving the research community for over 15 years.

DMCR has teamed up with Dr. Robina Poonawala, MD as principal investigator for their new Austin site. Located in South Asutin, this site has a great team to conduct clinical trials in a wide variety of therapeutic areas.

DMCR recently added Dr. Patricia Salvato to its list of Hub Sites in Houston. Dr. Salvato is an experienced investigator with over 20 years in research experience. Located in the heart of Houston, she has successfully proven her work with 2 clean FDA audits. She specializes in Internal Medicine; HIV and Infectious Disease

Introduction
Opening Doors for a Chance to Try Evolving Therapies

DM Clinical Research (DM) is a network of investigator sites based out of Houston, Texas. We are the link connecting pharmaceutical and research organizations to caring individuals seeking to power the advancement of medicine. We work with several qualified physicians with a diverse range of specialties and have conducted a wide variety of studies with successful enrollment targets. Our team of coordinators are highly educated and trained in medicine and research and include medical graduates.

 
 
Testimonial
"I have worked with many investigator sites and I have thoroughly enjoyed working with the DM research team as they are responsive, quality oriented and a overall pleasure to work with. It makes my job just a little bit easier!"


"We are the first Chinese Pharmaceutical company to conduct phase 2 clinical trials for a botanical drug product in the USA. We found DM Clinical Research, SMO, on the Internet. To my surprise, Mohammad A. Millwala, the CEO, and Syed, the Managing Director of DM were immediately engaged in our project, read through our protocols, and very professionally started the site identification process. DM is the one who enrolled the very first patient for our study and has the most patients randomized and completed so far, out of all of our 7 clinical sites! Over the year, the work of DM maintained its commitment to its clients: to provide good start up speed, credible research quality, and uninterrupted site-sponsor communications. I highly recommend DM to other pharmaceutical companies, especially to pharmaceutical companies who are conducting clinical research for alternative therapies."
Henry Sun, PhD. CBS
Vice President